Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myelome (IFM)

被引：8

作者：

Perrot, Aurore ^{[1
]}

Lauwers-Cances, Valerie ^{[2
]}

Touzeau, Cyrille ^{[3
]}

Decaux, Olivier ^{[4
]}

Hulin, Cyrille ^{[5
]}

Macro, Magaret ^{[6
]}

Stoppa, Anne-Marie ^{[7
]}

Chretien, Marie Lorraine ^{[8
]}

Karlin, Lionel ^{[9
]}

Mariette, Clara ^{[10
]}

Jacquet, Caroline ^{[11
]}

Roussel, Murielle ^{[12
]}

Guillemot, Coralie ^{[13
]}

Devlamynck, Laure ^{[2
]}

Avet-Loiseau, Herve ^{[14
]}

Moreau, Philippe ^{[15
]}

Attal, Michel ^{[16
]}

机构：

[1] Ctr Hosp Univ Toulouse, Serv Hematol, Toulouse, France

[2] CHU Toulouse, serv Epidemiol, USMR, Toulouse, France

[3] CHU Nantes, Hematol, Ctr Rech Cancerol & Immunol Nantes Angers CRCINA, Nantes, France

[4] CHU Rennes, Serv Hematol, Rennes, France

[5] Hop Haut Leveque, Univ Hosp, Pessac, France

[6] Ctr Hosp Univ CHU Caen, Caen, France

[7] Inst Paoli Calmettes, Marseille, France

[8] CHU Dijon, Serv Hematol Clin, Dijon, France

[9] Univ Claude Bernard Lyon 1, CHU Lyon Sud, Hosp Civils Lyon, Dept Hematol, Pierre Benite, France

[10] CHU Grenoble, Serv Hematol, Grenoble, France

[11] CHRU Nancy, Vandoeuvre Les Nancy, France

[12] CHU Limoges, Hematol, Limoges, France

[13] IUCT Oncopole, Pharm Unite Essais Clin, Toulouse, France

[14] UPS, CHU Toulouse, Unite Genom Myelome, IUCT Oncopole, Toulouse, France

[15] CHU Nantes, Nantes, France

[16] Inst Univ Canc Toulouse Oncopole, Toulouse, France

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-146040

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

464

引用

页数：5

共 50 条

[1] Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03)
Roussel, Murielle
Hebraud, Benjamin
Hulin, Cyrille
Leleu, Xavier
Facon, Thierry
Boyle, Eileen
Touzeau, Cyrille
Pegourie, Brigitte
Perrot, Aurore
Stoppa, Anne-Marie
Marolleau, Jean-Pierre
Moreau, Philippe
Avet-Loiseau, Herve
Devlamynck, Laure
Lauwers-Cances, Valerie
Attal, Michel
BLOOD, 2019, 134
[2] Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyeLome (IFM) Krd Phase II Study
Roussel, Murielle
Lauwers-Cances, Valerie
Robillard, Nelly
Belhadj, Karim
Facon, Thierry
Garderet, Laurent
Escoffre, Martine
Pegourie, Brigitte
Benboubker, Lotfi
Caillot, Denis
Fohrer, Cecile
Moreau, Philippe
Leleu, Xavier
Avet-Loiseau, Herve
Attal, Michel
BLOOD, 2016, 128 (22)
[3] Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyeLome (IFM)
Moreau, Philippe
Hulin, Cyrille
Caillot, Denis
Marit, Gerald
Perrot, Aurore
Garderet, Laurent
Facon, Thierry
Benboubker, Lotfi
Karlin, Lionel
Tiab, Mourad
Arnulf, Bertrand
Fermand, Jean-Paul
Leleu, Xavier
Touzeau, Cyrille
Roussel, Murielle
Planche, Lucie
Minvielle, Stephane
Bene, Marie-Christine
Avet-Loiseau, Herve
Dejoie, Thomas
Attal, Michel
BLOOD, 2016, 128 (22)
[4] Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014-03
Perrot, Aurore
Roussel, Murielle
Lauwers-Cances, Valerie
Hulin, Cyrille
Leleu, Xavier
Touzeau, Cyrille
Facon, Thierry
Mariette, Clara
Schiano, Jean-Marc
Gay, Julie
Montes, Lydia
Ranta, Dana
Huguet, Amandine
Wuilleme, Soraya
Dejoie, Thomas
Devlamynck, Laure
Corre, Jill
Avet-Loiseau, Herve
Moreau, Philippe
Attal, Michel
BRITISH JOURNAL OF HAEMATOLOGY, 2024,
[5] Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation ( ASCT) Followed By Ixazomib Maintenance Is a Safe and Effective Strategy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyeLome (IFM)
Moreau, Philippe
Hulin, Cyrille
Caillot, Denis
Marit, Gerald
Perrot, Aurore
Garderet, Laurent
Facon, Thierry
Benboubker, Lofti
Karlin, Lionel
Tiab, Mourad
Arnulf, Bertrand
Leleu, Xavier
Touzeau, Cyrille
Roussel, Murielle
Planche, Lucie
Avet-Loiseau, Herve
Dejoie, Thomas
Attal, Michel
BLOOD, 2017, 130
[6] Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk, transplant-eligible patients with newly diagnosed myeloma: Results of the phase 2 study IFM 2018-04.
Touzeau, Cyrille
Perrot, Aurore
Hulin, Cyrille
Manier, Salomon
Macro, Margaret
Caillot, Denis
Karlin, Lionel
Decaux, Olivier
Jacquet, Caroline
Tiab, Mourad
Leleu, Xavier
Planche, Lucie
Avet-Loiseau, Herve
Moreau, Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[7] Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myelome
Roussel, Murielle
Lauwers-Cances, Valerie
Robillard, Nelly
Hulin, Cyrille
Leleu, Xavier
Benboubker, Lotfi
Marit, Gerald
Moreau, Philippe
Pegourie, Brigitte
Caillot, Denis
Fruchart, Christophe
Stoppa, Anne-Marie
Gentil, Catherine
Wuilleme, Soraya
Huynh, Anne
Hebraud, Benjamin
Corre, Jill
Chretien, Marie-Lorraine
Facon, Thierry
Avet-Loiseau, Herve
Attal, Michel
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) : 2712 - +
[8] Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk transplant eligible newly diagnosed myeloma patients: results of the phase 2 study IFM 2018-04
Touzeau, Cyrille
Perrot, Aurore
Hulin, Cyrille
Manier, Salomon
Macro, Margaret
Chretien, Marie-Lorraine
Karlin, Lionel
Decaux, Olivier
Jacquet, Caroline
Tiab, Mourad
Leleu, Xavier
Planche, Lucie
Avet-Loiseau, Herve
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S25 - S25
[9] All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study
Touzeau, Cyrille
Perrot, Aurore
Roussel, Murielle
Karlin, Lionel
Benboubker, Lotfi
Jacquet, Caroline
Mohty, Mohamad
Facon, Thierry
Manier, Salomon
Chretien, Marie-Lorraine
Tiab, Mourad
Hulin, Cyrille
Leleu, Xavier
Loiseau, Herve Avet
Dejoie, Thomas
Planche, Lucie
Attal, Michel
Moreau, Philippe
HAEMATOLOGICA, 2022, 107 (07) : 1693 - 1697
[10] Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients
Joseph, Nisha
Kaufman, Jonathan
Lonial, Sagar
Hofmeister, Craig
Dhodapkar, Madhav
Gupta, Vikas
DiCamillo, Sara
Roberts, Danielle
Boise, Lawrence
Nooka, Ajay
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S113 - S113

← 1 2 3 4 5 →